Key result
Adriamycin adjuvant chemotherapy did not reduce distant metastasis compared to no chemotherapy (33.3% vs 33.3%) in early uterine sarcomas and caused severe heart failure, leading to trial termination.
Why the study?
Does doxorubicin reduce distant recurrences or improve objective response in women with uterine sarcomas?
RCT (n=29)
Does doxorubicin reduce distant recurrences or improve objective response in women with uterine sarcomas?
Doxorubicin showed minimal efficacy in uterine sarcomas and was associated with life-threatening cardiotoxicity, leading to early termination of the randomized trial.
Answers are grounded in this paper and cite their sources.
Avoid adjuvant doxorubicin in early uterine sarcomas; challenges prior assumptions of benefit and reinforces cardiotoxicity concerns.
Seventeen women with metastatic uterine sarcomas were treated with Adriamycin chemotherapy. Only one (6%) had an objective response. In addition, 12 patients with early uterine sarcomas were randomized to Adriamycin versus no adjuvant chemotherapy in order to evaluate the effect of Adriamycin in reducing the incidence of subsequent distant recurrences. Of those women receiving Adriamycin, two developed distant metastasis and two developed life-threatening congestive heart failure. Also, two of the six women who did not receive Adriamycin developed distant metastasis. Therefore, continuation of the randomized trial was considered unjustified.
No takes yet. Share an insight, caveat, or question.
Piver et al. (1979) conducted an RCT in Uterine sarcomas (n=29). Adriamycin vs. No adjuvant chemotherapy was evaluated on Distant recurrences. Adriamycin adjuvant chemotherapy did not reduce distant metastasis compared to no chemotherapy (33.3% vs 33.3%) in early uterine sarcomas and caused severe heart failure, leading to trial termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: